Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus for GvHD Prophylaxis After HSCT (OCTET-Ever)
NCT02812940Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Apr 2016
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in graft-versus-host disease (GVHD), sponsored by University of Cologne. Started Apr 2016; status: completed.
02
Drugs
everolimus
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02812940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02812940.